

# Lect. PhD DENİZ CANSEN KAHRAMAN

## Personal Information

**Office Phone:** [+90 0312 210 7374](tel:+9003122107374)

**Email:** [cansen@metu.edu.tr](mailto:cansen@metu.edu.tr)

**Web:** <https://avesis.metu.edu.tr/cansen>

### International Researcher IDs

ORCID: 0000-0002-3381-5463

Publons / Web Of Science ResearcherID: O-7515-2017

ScopusID: 57193092535

Yoksis Researcher ID: 318049

## Education Information

2011 - 2018	Doctorate, Ihsan Dogramaci Bilkent University, Faculty Of Science, Department Of Molecular Biology And Genetics, Turkey
2007 - 2011	Undergraduate, Ihsan Dogramaci Bilkent University, Faculty Of Science, Department Of Molecular Biology And Genetics, Turkey

## Foreign Languages

English, C1 Advanced

## Research Areas

Molecular Biology and Genetics, Molecular Biology of Cancer

## Academic Titles / Tasks

2020 - Continues	Lecturer PhD, Middle East Technical University, Graduate School of Informatics, Medical Informatics
------------------	---

## Courses

2019 - 2020	APPLICATIONS OF BIOINFORMATICS IN MOLECULAR BIOLOGY, Postgraduate
-------------	---

## Advising Theses

2023	Kahraman D. C., Muyan M., Postgraduate, E.AKAR(Student), MECHANISMS OF SYNERGISTIC ANTITUMOR EFFECT OF NAPROXEN AND SORAFENIB IN HEPATOCELLULAR CARCINOMA
2022	Kahraman D. C., Muyan M., Postgraduate, N.ECE(Student), IN VITRO AUTOCRINE SECRETION OF INFLAMMATORY CYTOKINES IN RESPONSE TO DRUG STRESS IN HCC AND LCSC POPULATIONS
2021	Kahraman D. C., Muyan M., Postgraduate, B.BINARCI(Student), BIOACTIVITY ANALYSIS OF NOVEL INDOLE DERIVATIVES ON HEPATOCELLULAR CARCINOMA AS SIRTUIN INHIBITORS

## Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Design, synthesis, molecular docking studies and biological evaluation of thiazole carboxamide derivatives as COX inhibitors**  
Hawash M., Jaradat N., Abualhasan M., ŞÜKÜROĞLU M. K., Qaoud M. T., KAHRAMAN D. C., Daraghmeh H., Maslamani L., Sawafta M., Ratrouf A., et al.  
BMC Chemistry, vol.17, no.1, 2023 (SCI-Expanded)
- II. **Novel indole-pyrazole hybrids as potential tubulin-targeting agents; Synthesis, antiproliferative evaluation, and molecular modeling studies**  
Hawash M., Ergun S. G., KAHRAMAN D. C., OLĞAÇ A., Hamel E., Cetin-Atalay R., BAYTAŞ S.  
Journal of Molecular Structure, vol.1285, 2023 (SCI-Expanded)
- III. **A new triazolothiadiazine derivative inhibits stemness and induces cell death in HCC by oxidative stress dependent JNK pathway activation**  
KAHRAMAN D. C., Guven E. B., Aytac P. S., Aykut G., Tozkoparan B., Atalay R. C.  
SCIENTIFIC REPORTS, vol.12, no.1, 2022 (SCI-Expanded)
- IV. **Design and synthesis of novel substituted indole-acrylamide derivatives and evaluation of their anti-cancer activity as potential tubulin-targeting agents**  
Hawash M., KAHRAMAN D. C., OLĞAÇ A., Ergun S. G., Hamel E., Cetin-Atalay R., BAYTAŞ S.  
JOURNAL OF MOLECULAR STRUCTURE, vol.1254, 2022 (SCI-Expanded)
- V. **Low Density Granulocytes and Dysregulated Neutrophils Driving Autoinflammatory Manifestations in NEMO Deficiency**  
Yilmaz N. S., Eltan S. B., KAYAOĞLU B., Geckin B., Heredia R. J., Sefer A. P., KIYKIM A., Nain E., Kasap N., DOĞRU Ö., et al.  
JOURNAL OF CLINICAL IMMUNOLOGY, vol.42, no.3, pp.582-596, 2022 (SCI-Expanded)
- VI. **Context dependent isoform specific PI3K inhibition confers drug resistance in hepatocellular carcinoma cells.**  
Narci K., Kahraman D. C., Koyas A., Ersahin T., Tuncbag N., Atalay R. C.  
BMC cancer, vol.22, no.1, pp.320, 2022 (SCI-Expanded)
- VII. **Synthesis of novel indole-isoxazole hybrids and evaluation of their cytotoxic activities on hepatocellular carcinoma cell lines**  
Hawash M., KAHRAMAN D. C., Ergun S. G., Cetin-Atalay R., BAYTAŞ S.  
BMC CHEMISTRY, vol.15, no.1, 2021 (SCI-Expanded)
- VIII. **Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells**  
Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.  
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol.221, 2021 (SCI-Expanded)
- IX. **Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation**  
Hawash M., Kahraman D. C., Cetin-Atalay R., BAYTAŞ S.  
CHEMISTRY & BIODIVERSITY, vol.18, no.5, 2021 (SCI-Expanded)
- X. **MDeePred: Novel multi-channel protein featurization for deep learning-based binding affinity prediction in drug discovery**  
Rifaioğlu A., Atalay R. C., KAHRAMAN D. C., DOĞAN T., Martin M., ATALAY M. V.  
Bioinformatics, vol.37, no.5, pp.693-704, 2021 (SCI-Expanded)
- XI. **Transcriptome profiles associated with selenium-deficiency-dependent oxidative stress identify potential diagnostic and therapeutic targets in liver cancer cells**  
Gozen D., KAHRAMAN D. C., Narci K., Shehwana H., KONU KARAKAYALI Ö., Cetin-Atalay R.  
TURKISH JOURNAL OF BIOLOGY, vol.45, no.2, pp.149-164, 2021 (SCI-Expanded)
- XII. **CXXC5 as an unmethylated CpG dinucleotide binding protein contributes to estrogen-mediated cellular proliferation.**  
Ayaz G., Razizadeh N., Yaşar P., Kars G., Kahraman D. C., Saatci Ö., Şahin Ö., Çetin-Atalay R., Muyan M.  
Scientific reports, vol.10, pp.5971, 2020 (SCI-Expanded)

- XIII. **Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment**  
KAHRAMAN D. C., Kahraman T., Cetin-Atalay R.  
MOLECULAR CANCER THERAPEUTICS, vol.18, no.11, pp.2146-2157, 2019 (SCI-Expanded)
- XIV. **Synthesis, anticancer activity, toxicity evaluation and molecular docking studies of novel phenylaminopyrimidine-(thio)urea hybrids as potential kinase inhibitors.**  
Ture A., Kahraman D. C., Cetin-Atalay R., Helvacioğlu S., Charehsaz M., KÜÇÜKGÜZEL İ.  
Computational biology and chemistry, vol.78, pp.227-241, 2019 (SCI-Expanded)
- XV. **Design, synthesis and biological evaluation of novel 1,3-diarylpyrazoles as cyclooxygenase inhibitors, antiplatelet and anticancer agents.**  
Inceler N., ÖZKAN Y., Turan N. N., Kahraman D. C., Cetin-Atalay R., BAYTAŞ S.  
MedChemComm, vol.9, no.5, pp.795-811, 2018 (SCI-Expanded)
- XVI. **Synthesis and biological evaluation of novel pyrazolic chalcone derivatives as novel hepatocellular carcinoma therapeutics.**  
Hawash M. M. A., Kahraman D. C., Eren F., Atalay R. C., BAYTAŞ S.  
European journal of medicinal chemistry, vol.129, pp.12-26, 2017 (SCI-Expanded)
- XVII. **Quinoides and VEGFR2 TKIs influence the fate of hepatocellular carcinoma and its cancer stem cells.**  
Kahraman D. C., Hanquet G., Jeanmart L., Lanners S., Sramel P., Bohac A., Cetin-Atalay R.  
MedChemComm, vol.8, no.1, pp.81-87, 2016 (SCI-Expanded)
- XVIII. **Phase and TV Based Convex Sets for Blind Deconvolution of Microscopic Images**  
Tofighi M., Yorulmaz O., Koese K., Yildirim D. C., Cetin-Atalay R., ÇETİN A. E.  
IEEE JOURNAL OF SELECTED TOPICS IN SIGNAL PROCESSING, vol.10, no.1, pp.81-91, 2016 (SCI-Expanded)
- XIX. **Ynamide Click chemistry in development of triazole VEGFR2 TK modulators.**  
Vojtickova M., Dobias J., Hanquet G., Addova G., Cetin-Atalay R., Yildirim D. C., Bohac A.  
European journal of medicinal chemistry, vol.103, pp.105-22, 2015 (SCI-Expanded)
- XX. **Application of the Ugi reaction with multiple amino acid-derived components: synthesis and conformational evaluation of piperazine-based minimalist peptidomimetics.**  
Stucchi M., Cairati S., Cetin-Atalay R., Christodoulou M. S., Grazioso G., Pescitelli G., Silvani A., Yildirim D. C., Lesma G.  
Organic & biomolecular chemistry, vol.13, no.17, pp.4993-5005, 2015 (SCI-Expanded)
- XXI. **Near-IR absorbing BODIPY derivatives as glutathione-activated photosensitizers for selective photodynamic action.**  
Turan I., Cakmak F., Yildirim D. C., Cetin-Atalay R., Akkaya E.  
Chemistry (Weinheim an der Bergstrasse, Germany), vol.20, pp.16088-92, 2014 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools**  
Cetin-Atalay R., Kahraman D. C., Nalbat E., Rifaioğlu A. S., Atakan A., Dönmez A., Atas H., Atalay M. V., Acar A. C., Doğan T.  
JOURNAL OF GASTROINTESTINAL CANCER, vol.52, no.4, pp.1266-1276, 2021 (ESCI)

## Refereed Congress / Symposium Publications in Proceedings

- I. **Repurposing Drugs to Target Molecular Networks in Hepatocellular Carcinoma Cells & Stem Cells for Innovative Treatment Strategies**  
NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.  
4th Open Research Day, Turkey, 01 December 2023
- II. **Network-based drug repurposing approach identifies novel drugs and drug combinations against**

## HCC

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

AASLD-TASL Digital Hepatology Meeting, Ankara, Turkey, 28 - 29 April 2023

- III. **A NEW THIADIAZINE DERIVATIVE INDUCES OXIDATIVE STRESS DEPENDENT CELL DEATH IN HEPATOCELLULAR CARCINOMA STEM CELLS**  
KAHRAMAN D. C., GÜVEN E. B., AYTAC P., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.  
Annual Meeting of the American-Association-for-the-Study-of-Liver-Diseases (AASLD) / Liver Meeting, Massachusetts, United States Of America, 8 - 12 November 2019, vol.70
- IV. **In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma**  
Sinoplu E., Tuncbag N., Kahraman D. C., Atalay R. C.  
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, United States Of America, 29 March - 03 April 2019, vol.79
- V. **A new thiadiazine derivative induces oxidative stress dependent JNK pathway activation and cell death in hepatocellular carcinoma**  
KAHRAMAN D. C., GÜVEN E. B., TOZKOPARAN KÖPRÜCÜ B., ATALAY R.  
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, United States Of America, 29 March - 03 April 2019, vol.79
- VI. **Differential alteration of IL-8 in liver cancer stem cell enrichment in response to PI3K/Akt/mTOR inhibitors and sorafenib**  
Kahraman D. C., Kahraman T., ATALAY R.  
American Association for Cancer Research Annual Meeting 2018, Chicago, United States Of America, 12 - 18 April 2018, vol.78, pp.3937
- VII. **Abstract LB-A08: Differential alteration of IL-8 in response to Sorafenib and PI3K/Akt/mTOR inhibitors in liver cancer cells and in liver cancer stem cells**  
Kahraman D. C., ATALAY R.  
AACR-NCI-EORTC International Conference, Philadelphia, 26 - 30 October 2017
- VIII. **HEPATOCELLULAR CARCINOMA TERAPEUTICS: SYNTHESIS AND BIOLOGICAL EVALUATION INDOLE-3-CARBOXAMIDES**  
Kılıç E. K., Kahraman D. C., ATALAY R., BAYTAŞ S.  
2nd International Gazi Pharma Symposium, 11 - 13 October 2017
- IX. **ANTICANCER EFFECTS OF NEW INDOLE -PYRAZOLE AND ONDOLE-OSOXAZOLE HYBRIDS DESIGN, SYNTHESIS AND EVALUATION OF ACTIVITY**  
Hawash M. M., Kahraman D. C., ATALAY R., BAYTAŞ S.  
2nd International Gazi Pharma Symposium, 11 - 13 October 2017
- X. **Induction of Apoptosis in Hepatocellular Carcinoma Cell Lines by Novel Indolylacrylamide Derivatives: Synthesis and Biological Evaluation**  
Hawash M., Kahraman D. C., ATALAY R., BAYTAŞ S.  
26th ISHC Congress on Heterocyclic Chemistry, 3 - 08 September 2017
- XI. **Dielectrophoretic Spectra of CD133+/EpCAM+ HUH7 Cancer Stem Cells and HUH7 Cancer Cells**  
Çağlayan Z., Demircan Yalçın Y., Özkayar G., Kahraman D. C., Atalay R., Özgür E., Külah H.  
Dielectrophoresis 2016, Massachusetts, United States Of America, 13 - 15 July 2016, pp.1-4
- XII. **Sequential treatment of HCC cells with PI3K Akt mTOR pathway inhibitors prior to sorafenib attenuates cancer stem cell population**  
Kahraman D. C., Kahraman T., ATALAY R.  
EACR 27, 1 - 04 July 2016, vol.61, pp.77

## Supported Projects

2023 - 2026

Hepatosellüler Karsinomada Hippo Sinyal Yolağı Hedefli Bileşiklerin Mekanizmasının Aydınlatılması, TUBITAK Project

2022 - 2025	Öncü Bileşik Optimizasyonu ile Tasarlanan Antikanser Etkili Olabilecek Yeni Bileşiklerin Sentezi, Yapı-Etki İlişkileri ve Moleküler Etki Mekanizmalarının İncelenmesi, TUBITAK Project
2020 - 2023	Hepatosellüler Kansere Özgü Ctdna Tayini İçin Düşük Enerji İle Uyarılabilen Ve Çoklu Analize Olanak Sağlayan Mikroakışkan Tabanlı Ve Üst-Çevirici Nanopartikül-Kuantum Nokta Hibrid Yapılı Fotoelektrokimyasal Sensörün Geliştirilmesi, TUBITAK Project
2020 - 2022	Derin Öğrenme Bazlı Farmakogenomik Modelleme İle Geniş Çaplı Kanser Hücre Hattı İlaç Yantı Tahmini, Research Project of the Presidency of Turkey Health Institutes (TÜSEB)

## Memberships / Tasks in Scientific Organizations

2019 - Continues	American Association for the Study of Liver Diseases (AASLD), Member
2019 - Continues	Türk Karaciğer Araştırmaları Derneği, Member
2017 - Continues	American Association for Cancer Research (AACR), Member
2016 - Continues	Moleküler Kanser Araştırma Derneği (MOKAD), Member
2016 - Continues	European Association for Cancer Research (EACR), Member

## Metrics

Publication: 34  
Citation (WoS): 278  
Citation (Scopus): 248  
H-Index (WoS): 8  
H-Index (Scopus): 8

## Awards

September 2023	Young Basic Cancer Researcher Award, Moleküler Kanser Araştırmaları Derneği (Mokad)
August 2019	International Early Career Investigator Award, American Association For The Study Of Liver Diseases
May 2019	Special Mention Poster Award, Enformatik Enstitüsü, Metu
October 2017	Best Poster Award, 5Th International Bau Drug Design Congress